📌 Key Takeaways
✔ The global aesthetic injectables market is projected to reach approximately $29 billion by 2032✔ 2026 marks a turning point as the shift toward regenerative medicine accelerates
✔ Simultaneously, the UK is advancing tighter regulations on high-risk aesthetic procedures
✔ AI-driven diagnostics are becoming increasingly standardized
Facial “lumps” that do not disappear.
Three women who underwent Premium PRP Skin Regeneration Therapy at a Tokyo clinic have filed a lawsuit in Tokyo District Court, seeking approximately ¥18.5 million in damages, alleging the development of persistent lumps and skin irregularities.
The issue at stake is not merely medical complications.
Within Japan’s framework for regenerative medicine—often provided as private, self-paid treatment—the central question is whether off-label use of PRP combined with bFGF was adequately explained to patients prior to injection.
NERO has previously reported on complication cases and the regulatory positioning of this therapy.
This lawsuit signals that the debate has now moved from clinical discussion to the courtroom.
As innovation accelerates in aesthetic medicine, the issue under scrutiny is no longer simply technology—
but the architecture of disclosure and accountability.
INDEX
What Happened
At a Tokyo aesthetic clinic, three women received Premium PRP Skin Regeneration Therapy and later reported:
• Lumps under the eyes and cheeks
• Skin protrusions
• Ongoing disruption to daily life
They claim they were not sufficiently informed of the risks before undergoing treatment.
The plaintiffs argue that informed consent requirements were not properly fulfilled.
What Is “Premium PRP”?
The treatment in question involves PRP (Platelet-Rich Plasma) combined with bFGF (basic fibroblast growth factor).
PRP itself is a regenerative therapy derived from a patient’s own blood.
However, bFGF is originally approved in Japan as a topical wound-healing agent, not as an injectable product.
Pharmaceutical guidance states that the safety and efficacy of injectable administration have not been established.
The Japanese Society of Aesthetic Plastic Surgery has also issued a statement noting:
Due to frequent reports of complications and insufficient safety assurance, the society “weakly recommends against” performing bFGF-added PRP therapy.
Misconceptions Spreading Online
Following media coverage, debate has reignited on X (formerly Twitter), with some questioning whether PRP itself is dangerous.
However, the core issue in this case is not PRP alone, but PRP combined with bFGF.
PRP has long been used in orthopedics and sports medicine.
In aesthetic practice, additive formulations have emerged, raising questions about safety profiles and risk communication.
The problem is not “PRP = dangerous.”
The issue is whether additive use was appropriately disclosed and understood.
More Than a Complication Case
The lawsuit raises critical questions:
✔ Was off-label use clearly explained?
✔ Were patients informed that certain effects could be long-lasting or permanent?
✔ Were obligations under Japan’s Regenerative Medicine Act fully satisfied?
At a press conference, one plaintiff stated:
“Every time I look in the mirror, I feel despair.”
Another said:
“I was told, ‘It looks successful.’”
The central issue may not be the technology itself, but the sincerity and transparency of its explanation.
In addition, a legal advocacy group has announced a dedicated hotline for individuals who may have experienced similar complications related to bFGF-added PRP, suggesting the matter may extend beyond a single case.
Editor’s Perspective — Is This a Technology Issue?
Regenerative medicine remains an important and growing field.
However, when the following three factors intersect:
• Private regenerative procedures
• Off-label use
• Rapid expansion of the aesthetic market
The question becomes whether informed consent quality has kept pace with innovation.
Japan’s aesthetic medicine sector appears to be shifting:
From a phase of technological expansion
To a phase of governance, transparency, and explanation.
“Regenerative” is an appealing word.
But its future depends on accountability.
This case is not merely about medical advancement—
it is about the design of trust.
Conclusion
• ¥18.5 million lawsuit filed over Premium PRP therapy
• Core issue centers on informed consent, not only complications
• Regulatory oversight under the Regenerative Medicine Act may be examined
• The aesthetic field is entering an era where explanation matters as much as technique
This case goes beyond one clinic.
As regenerative medicine expands within aesthetics,
how it is implemented—and how risks are communicated—will shape the future of the industry.
As legal proceedings unfold, the standards set by the judiciary may influence the next phase of Japan’s aesthetic medicine landscape.
NERO will continue to monitor developments closely.
Source
Sankei News
“‘Every time I look in the mirror, I feel despair’: Women file lawsuit against Tokyo clinic over facial lumps after cosmetic treatment”
Published February 27, 2026
NERO’s Mission
NERO reports on global developments in aesthetic medicine
through the lens of structure, ethics, and long-term consequence.
Rather than amplifying surface-level trends,
we examine how medical practices are regulated, commercialised, and normalised —
and what is reshaped when innovation moves faster than existing frameworks.
As aesthetic medicine expands beyond traditional clinical boundaries,
NERO focuses on the grey zones where definitions blur, responsibilities shift,
and medical decision-making becomes increasingly complex.
In an era of accelerating innovation,
NERO remains committed to transparency, critical scrutiny,
and responsible reporting —
so readers can understand not only what is new,
but what deserves closer examination before it becomes standard practice.
